Une vision stratégique de l'actualité scientifique et technologique du secteur des biotechnologies.

Feedback on the Japan 2016 business mission

bioxclusters_logo_plus_horizontalSimon Gudin, SMEs Development Manager at LyonBiopôle.

The Japanese healthcare market, the second largest in the world after the United States, is also very dynamic, with a recent opening of Japanese Pharma to Open innovation and the search for new solutions worldwide. It is therefore a target market for Lyonbiopôle, its European partners in bioXclusters Plus – Biocat, BioM and BioPmed – and their companies. This is why the alliance organised a trade mission with 26 European companies to Bio Japan 2016. For the 3rd consecutive year, 6 members of Lyonbiopôle were part of the trip with the support of the Auvergne-Rhône-Alpes region: CTI Biotech, Indicia Biotech, Theranexus, Novotec-Labs, Cytoo and Genoway.

This mission was the occasion to organize the 1st edition of the European Biotech & Pharma Partnering Conference in Osaka in collaboration with the Osaka Bio Headquarters and the Eu-Japan Center for Industrial Cooperation. After a first day of training dedicated to key information on the healthcare market in Japan, this meeting allowed 53 European companies and 97 Japanese to participate in 289 individual business meetings. The mission then continued with the BioJapan business convention in Yokohama.

Following this 2016 mission, bioXclusters Plus signed a cooperation agreement with Osaka Bio Headquarters. The agreement promotes a closer cooperation between the two parties and their companies. In particular, they will facilitate access to the European and Japanese markets and to promote and co-organize events that foster the rapprochement of their companies.

Similar posts

Aucun commentaire jusqu'à présent.

Laisser un commentaire

Dernière Lettre parue

Cliquez sur l'image pour accéder à la lecture via Calaméo (accès réservé aux abonnés)
Cliquez sur l'image pour accéder à la lecture via Calaméo (accès réservé aux abonnés)

Abonnement

(abonnement aux éditions de la Lettre et accès intégral au site)

Abonnez-vous à notre newsletter gratuite